You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CUDC-101

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CUDC-101?

CUDC-101 is an investigational drug.

There have been 12 clinical trials for CUDC-101. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Lymphoma, Head and Neck Neoplasms, and Thyroid Carcinoma, Anaplastic. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Aarhus University Hospital.

There are twenty US patents protecting this investigational drug and three hundred and sixty-four international patents.

Recent Clinical Trials for CUDC-101
TitleSponsorPhase
The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.Aarhus University HospitalPhase 1
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid CancerNational Cancer Institute (NCI)Phase 2
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCuris, Inc.Phase 1

See all CUDC-101 clinical trials

Clinical Trial Summary for CUDC-101

Top disease conditions for CUDC-101
Top clinical trial sponsors for CUDC-101

See all CUDC-101 clinical trials

US Patents for CUDC-101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CUDC-101   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
CUDC-101   Start Trial Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Start Trial
CUDC-101   Start Trial Compositions and methods for treating kabuki syndrome and related disorders THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD)   Start Trial
CUDC-101   Start Trial Quinazoline based EGFR inhibitors containing a zinc binding moiety Curis, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CUDC-101

Drugname Country Document Number Estimated Expiration Related US Patent
CUDC-101 Australia 2012328780 2031-10-25   Start Trial
CUDC-101 Australia 2013226031 2031-10-25   Start Trial
CUDC-101 Australia 2013226034 2031-10-25   Start Trial
CUDC-101 Australia 2013271436 2031-10-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.